



## Our Impact This Year

### 2021 Annual Report



## A Message From The President of NATF

Dear Friends:

Educating patients, families, and healthcare providers about thrombotic illnesses has been a primary focus for NATF since its inception in 2006. NATF continues to expand our reach beyond blood clots to include related conditions, such as cancer, diabetes, and heart disease. I am particularly excited to share a notable milestone that we achieved in 2021. For the first time since NATF was founded, we reached more than 1 million healthcare providers and patients globally through our educational initiatives, a new website, and revamped social media platforms.

In 2021, NATF also developed educational formats for the “new normal.” As the COVID-19 pandemic continued, we principally focused on hybrid programs that combined interactive distance learning with live, in-person interactions. We successfully (and safely) hosted our first-ever hybrid programs in the fall: the U.S. CTEPH Proceedings in Philadelphia and the Right Heart Symposium in Boston.

COVID and thrombosis remained a topic for us throughout 2021. We started off the year with a virtual program titled, “COVID, Thrombosis and Research: Steering the Storm with Full Sails” and closed out the year with our annual Thrombosis

Summit, “Living in a Post-Pandemic World: What Medicine Has Learned in the Last Year.”

We hosted monthly virtual support groups for patients, added the first patient representative to the Board of Directors, and secured \$1,000,000 in grant/sponsorship revenue. These landmark achievements were made possible by unprecedented teamwork and collaboration with patients, their families and friends, healthcare providers, academicians, and industry partners.

I owe a special debt of gratitude to Kathryn Mikkelsen, NATF Executive Director, to Courtney Anderson, Director of Operations, to Aviva Schwartz, Director of Content and Education and Co-Chair of NATF’s Medical Advisory Board, and to Maggie Newberg, Associate Director of Marketing.

With appreciation and gratitude for your continued support of NATF,

A handwritten signature in black ink, reading "S. Z. Goldhaber".

Samuel Z. Goldhaber, MD  
President, NATF  
Associate Chief and Clinical Director  
Division of Cardiovascular Medicine  
Professor of Medicine  
Harvard Medical School



## A Message From The NATF Staff

Dear Friends and Supporters:

In the 2020 Annual Report, we answered the question “where does NATF go from here?” and laid out our plans to double down on educating both healthcare providers and patients, continue expanding our reach beyond blood clots to include related conditions (such as cancer and heart disease), and to address health disparities and inequities by creating more resources for marginalized populations. With great pride and pleasure, we can officially share that we accomplished all of these goals in 2021:

- **For the first time since NATF was founded in 2006, we educated over 1 million patients and healthcare providers about blood clots and related cardiovascular diseases.**
- We engaged a nationwide group of experts from a broad range of specialties (including two patients) to draft guidance on assessing and addressing blood clots in transgender patients.
- We added the first patient representative to the NATF Board of Directors.
- We safely hosted two hybrid educational programs for clinicians: The U.S. CTEPH Proceedings in Philadelphia, PA and the Right Heart Symposium in Boston, MA.
- We committed to having more diversity among our program faculty.

- We engaged a health literacy expert to make our patient education accessible to a broader audience.

Despite the ongoing challenges we faced in 2021, we managed to make a tremendous impact. As the saying goes, “it takes a village.” We could not have done a fraction of this work without the tireless support of the healthcare providers and scientists who volunteer their time to help us create our state-of-the-art educational materials, the patients who join our support groups to share their stories and lend encouragement to one another, and, of course, you, our generous donors, who entrust us to put your donations to the best possible use.

With whatever global challenges may come our way, the vision for NATF remains the same: to be the leader in the fight against blood clots.

We know this vision is attainable if we continue to work together.

Thank you for your generous support of NATF.

Warm regards,


*Kathryn Mikkelson* *Aviva Schwartz*  
*Courtney Anderson* *Margaret Nubling*

Kathryn, Courtney, Aviva, and Maggie



## How NATF Made an Impact This Year

Through our innovative programs and educational initiatives, we educated over 1 million patients and healthcare providers about blood clots and related cardiovascular diseases.



## Hosted our first-ever hybrid courses in Philadelphia, PA and Boston, MA



The U.S. CTEPH Proceedings, hosted in Philadelphia, PA, provided a multidisciplinary framework for the evaluation and management of patients with chronic thromboembolic pulmonary hypertension (CTEPH). The program featured national and international experts in the field.

The Right Heart Symposium, hosted in Boston, MA, addressed the syndrome of right heart failure, which is poorly understood and defined. A renowned panel of multidisciplinary, internationally renowned experts came together to discuss the latest research and advances in right heart syndromes.






## Hosted our second virtual Thrombosis Summit: *"Living in a Post-Pandemic World: What Medicine Has Learned in the Last Year"*

This program focused on key lessons learned during the COVID-19 pandemic, including how mRNA vaccine technology may be leveraged in cardiovascular medicine, what we know about thromboinflammation in COVID-19, the potential effects of long COVID syndrome on our patients and the healthcare system, and how clinicians can begin to address both consequences of delayed cardiac care and the myriad healthcare inequities that have been uncovered during the pandemic.

## Continued the *Ask the Expert* series

This live forum addressed pressing questions that patients had. Experts answered questions about the COVID-19 vaccine, starting and stopping anticoagulation for a procedure or surgery, anticoagulation in patients with cancer, anticoagulation and COVID-19, and the COVID-19 vaccine.



Themio Papadopoulos, PharmD

Andrea Lewin, PharmD



John Fanikos, RPh, MBA




Beata Rucinski, PharmD



## 2021 Expense Report

In 2021, you helped NATF support life-changing programs by raising \$121,549 for the Annual Fund.



# Donor Honor Roll of 2021

The Annual Report reflects all gifts and pledges received in 2021

## CORPORATE PARTNERS OF NATF

Abbott Laboratories  
Accelaron Pharma  
Actelion Pharmaceuticals  
Altavant  
AstraZeneca  
Bayer  
Boston Scientific  
Bristol-Myers Squibb  
The Bristol-Myers Squibb-Pfizer  
Alliance  
Janssen Pharmaceuticals, Inc.  
United Therapeutics

## PARTNERS OF NATF (\$15,000+)

Steve and Georgianne Roberts  
– *In honor of Dr. Samuel  
Goldhaber*  
Charles Binder and Nancy Shor  
– *In honor of Dr. Samuel  
Goldhaber's granddaughter*

## BENEFACTORS OF NATF (\$5,000-\$14,999)

Rachel and Timothy Burns  
– *In honor of Rosemary Pye*  
Beth and Joseph P. Kennedy II  
Reeve and Samuel Goldhaber,  
MD  
Leslee and Randy Greene

## PATRONS OF NATF (\$1,000-\$4,999)

Anonymous BMS Employee  
Rose and John H. Ashby, JD  
– *In honor of Dr. Samuel  
Goldhaber*  
William R. Auger, MD  
Jake Barnes  
– *In honor of Dr. Quac-Dien  
Trinh*  
Black Diamond Networks, LLC  
Marsha and Jonathan Byrnes  
David J. Chavolla, JD  
– *In honor of John Ashby*  
The Honorable E. George Daher  
Todd Ellis  
Marlene and Dennis Hurley  
Christina Martin  
– *In loving memory of Manu  
"Shaq" Williams*  
Alan Marshall Meckler  
– *In honor of Dr. Samuel  
Goldhaber*  
Laura and Greg Milmo  
– *In honor of Dr. Samuel  
Goldhaber*  
Bryce Mochrie  
Rosemary Pye, JD  
Drs. Christian Ruff and Tara  
Kieffer  
Alfred Serring Jr.  
Brenda Shisslak

## SUPPORTERS OF NATF (\$250-\$999)

Behnood Bikdeli, MD, MS  
Denise Cardo  
– *In memory of Dr. Ken Leeper*  
Gail and Leroy Clark  
Jeffrey Condlin  
– *In memory of Stephanie Maria  
Condlin*  
Paul Dello Iacono  
John and Lynne Iberg  
Martha Lindsay  
Harold Mahoney  
Don Strange  
Suresh Vedantham, MD

Joy Vlachos  
– *In honor of Drs. Umberto  
Campia, Samuel Goldhaber,  
and Gregory Piazza*  
Alan Weiss

## FRIENDS OF NATF (\$50-\$249)

Teresa Carman, MD  
Bartley Coyne and Diane  
Mazzaferro  
Sandra Czibik  
Leonard and Linda Delvecchio  
Rick Dew  
Martin and Judy Dorf  
Alissa Goldhaber  
– *In honor of Dr. Samuel  
Goldhaber*  
James H. Griffiths  
Mary E. Hoffman  
– *In honor of Dr. Samuel  
Goldhaber*  
Susan Holzman, MD  
– *In honor of Dr. Samuel  
Goldhaber*  
Patricia Hurd  
Dennis Kelley  
Carol Kresse  
Barbara Lucas  
Linda and Ed Lyon  
Frederick and Pauline Metters  
Network for Good  
David C. Osler, MD  
Tarry Plattner  
Karen Roberts  
Sheryl and Joseph H. Schwartz,  
MD  
– *In honor of Emery Olivia  
Leeming*  
Julie Sharp  
Martha Stassinis  
Peter Weinberg, MD

## DONORS OF NATF (\$1-\$49)

Courtney Anderson  
Benevity  
Lenore Lipworth  
– *In honor of Dr. Samuel  
Goldhaber*  
Albert and Katherine Mitchell

Connect with us on social media!



@NATFThrombosisForum



@NATFthrombosis



@NorthAmericanThrombosis



@NorthAmericanThrombosisForum



@NorthAmericanThrombosisForum



*Fighting blood clots  
through education*

Copyright © 2022 North American Thrombosis Forum.

All Rights Reserved. NATF is a 501(c)(3) nonprofit.

NORTH AMERICAN THROMBOSIS FORUM

368 Boylston Street, Brookline, MA 02445

[thrombosis.org](http://thrombosis.org)

617-730-4120